Yingqian Ada Zhan

Yingqian Ada Zhan

Auto-generated profile, based on publicly available information

Yingqian Ada Zhan

Center for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New York, USA

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2021 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
AQAlvaro Quintanal
Alvaro Quintanal
HTHirokazu Taniguchi
Hirokazu Taniguchi
YZYingqian A. Zhan
Yingqian A. Zhan
MHMaysun M. Hasan
Maysun M. Hasan
SCShweta S. Chavan
Shweta S. Chavan
TSTriparna Sen
Triparna Sen
Lineage plasticity is implicated in treatment resistance in multiple cancers. In lung adenocarcinomas (LUAD) amenable to targeted therapy, transformation to small cell lung cancer (SCLC) is a recognized resistance mechanism. Defining molecular mechanisms of neuroendocrine (NE) transformation in lung cancer has been limited by a paucity of pre/posttransformation clinical samples. Detailed genomic, epigenomic, transcriptomic, and protein characterization of combined LUAD/SCLC tumors, as well as pre/posttransformation samples, supports that NE transformation is primarily driven by transcriptional reprogramming rather than mutational events. We identify genomic contexts in which NE transformation is favored, including frequent loss of the 3p chromosome arm. We observed enhanced expression of genes involved in the PRC2 complex and PI3K/AKT and NOTCH pathways. Pharmacologic inhibition of the PI3K/AKT pathway delayed tumor growth and NE transformation in an EGFR-mutant patient-derived xenograft model. Our findings define a novel landscape of potential drivers and therapeutic vulnerabilities of NE transformation in lung cancer. Significance: The difficulty in collection of transformation samples has precluded the performance of molecular analyses, and thus little is known about the lineage plasticity mechanisms leading to LUAD-to-SCLC transformation. Here, we describe biological pathways dysregulated upon transformation and identify potential predictors and potential therapeutic vulnerabilities of NE transformation in the lung. See related commentary by Meador and Lovly, p. 2962. This article is highlighted in the In This Issue feature, p. 2945

8 February 2023 in Nature
Verified
Journal Article
Open access
PDF file
NJNayan Jain
Nayan Jain
ZZZeguo Zhao
Zeguo Zhao
JFJudith Feucht
Judith Feucht
RKRichard Koche
Richard Koche
AIArchana Iyer
Archana Iyer
MSMichel Sadelain
Michel Sadelain
Further advances in cell engineering are needed to increase the efficacy of chimeric antigen receptor (CAR) and other T cell-based therapies1,2,3,4,5. As T cell differentiation and functional states are associated with distinct epigenetic profiles6,7, we hypothesized that epigenetic programming may provide a means to improve CAR T cell performance. Targeting the gene that encodes the epigenetic regulator ten–eleven translocation 2 (TET2)8 presents an interesting opportunity as its loss may enhance T cell memory9,10, albeit not cause malignancy9,11,12. Here we show that disruption of TET2 enhances T cell-mediated tumour rejection in leukaemia and prostate cancer models. However, loss of TET2 also enables antigen-independent CAR T cell clonal expansions that may eventually result in prominent systemic tissue infiltration. These clonal proliferations require biallelic TET2 disruption and sustained expression of the AP-1 factor BATF3 to drive a MYC-dependent proliferative program. This proliferative state is associated with reduced effector function that differs from both canonical T cell memory13,14 and exhaustion15,16 states, and is prone to the acquisition of secondary somatic mutations, establishing TET2 as a guardian against BATF3-induced CAR T cell proliferation and ensuing genomic instability. Our findings illustrate the potential of epigenetic programming to enhance T cell immunity but highlight the risk of unleashing unchecked proliferative responses.

17 May 2022 in Cell Reports
Verified
Journal Article
Open access
HTHirokazu Taniguchi
Hirokazu Taniguchi
RCRebecca Caeser
Rebecca Caeser
SCShweta S. Chavan
Shweta S. Chavan
YZYingqian A. Zhan
Yingqian A. Zhan
ACAndrew Chow
Andrew Chow
TSTriparna Sen
Triparna Sen
Small cell lung cancers (SCLCs) have high mutational burden but are relatively unresponsive to immune checkpoint blockade (ICB). Using SCLC models, we demonstrate that inhibition of WEE1, a G2/M checkpoint regulator induced by DNA damage, activates the STING-TBK1-IRF3 pathway, which increases type I interferons (IFN-α and IFN-β) and pro-inflammatory chemokines (CXCL10 and CCL5), facilitating an immune response via CD8+ cytotoxic T cell infiltration. We further show that WEE1 inhibition concomitantly activates the STAT1 pathway, increasing IFN-γ and PD-L1 expression. Consistent with these findings, combined WEE1 inhibition (AZD1775) and PD-L1 blockade causes remarkable tumor regression, activation of type I and II interferon pathways, and infiltration of cytotoxic T cells in multiple immunocompetent SCLC genetically engineered mouse models, including an aggressive model with stabilized MYC. Our study demonstrates cell-autonomous and immune-stimulating activity of WEE1 inhibition in SCLC models. Combined inhibition of WEE1 plus PD-L1 blockade represents a promising immunotherapeutic approach in SCLC.

2 March 2021 in Molecular Cell
Verified
Journal Article
Closed access
ARAliaksandra Radzisheuskaya
Aliaksandra Radzisheuskaya
PSPavel V. Shliaha
Pavel V. Shliaha
VGVasily V. Grinev
Vasily V. Grinev
DSDaria Shlyueva
Daria Shlyueva
HDHelene Damhofer
Helene Damhofer
KHKristian Helin
Kristian Helin

27 September 2024 in Science Advances
Verified
Journal Article
Open access
HTHirokazu Taniguchi
Hirokazu Taniguchi
SCSubhamoy Chakraborty
Subhamoy Chakraborty
NTNobuyuki Takahashi
Nobuyuki Takahashi
ABAvisek Banerjee
Avisek Banerjee
RCRebecca Caeser
Rebecca Caeser
TSTriparna Sen
Triparna Sen
Patients with small-cell lung cancer (SCLC) have poor prognosis and typically experience only transient benefits from combined immune checkpoint blockade (ICB) and chemotherapy. Here, we show that inhibition of ataxia telangiectasia and rad3 related (ATR), the primary replication stress response activator, induces DNA damage–mediated micronuclei formation in SCLC models. ATR inhibition in SCLC activates the stimulator of interferon genes (STING)–mediated interferon signaling, recruits T cells, and augments the antitumor immune response of programmed death-ligand 1 (PD-L1) blockade in mouse models. We demonstrate that combined ATR and PD-L1 inhibition causes improved antitumor response than PD-L1 alone as the second-line treatment in SCLC. This study shows that targeting ATR up-regulates major histocompatibility class I expression in preclinical models and SCLC clinical samples collected from a first-in-class clinical trial of ATR inhibitor, berzosertib, with topotecan in patients with relapsed SCLC. Targeting ATR represents a transformative vulnerability of SCLC and is a complementary strategy to induce STING-interferon signaling–mediated immunogenicity in SCLC.

4 December 2024 in Nature
Verified
Journal Article
Closed access
PDF file
XZXueqian Zhuang
Xueqian Zhuang
QWQing Wang
Qing Wang
SJSimon Joost
Simon Joost
AFAlexander Ferrena
Alexander Ferrena
DHDavid T. Humphreys
David T. Humphreys
TTTuomas Tammela
Tuomas Tammela